- Home
- ATER vs CVKD Comparison
ATER vs CVKD Comparison
Compare ATER & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATER
- CVKD
- Stock Information
- Founded
- ATER 2014
- CVKD 2022
- Country
- ATER United States
- CVKD United States
- Employees
- ATER N/A
- CVKD N/A
- Industry
- ATER Home Furnishings
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- ATER Consumer Discretionary
- CVKD Health Care
- Exchange
- ATER Nasdaq
- CVKD Nasdaq
- Market Cap
- ATER 22.8M
- CVKD 20.8M
- IPO Year
- ATER N/A
- CVKD 2023
- Fundamental
- Price
- ATER $2.18
- CVKD $12.96
- Analyst Decision
- ATER Strong Buy
- CVKD Strong Buy
- Analyst Count
- ATER 1
- CVKD 2
- Target Price
- ATER N/A
- CVKD $46.00
- AVG Volume (30 Days)
- ATER 71.8K
- CVKD 64.9K
- Earning Date
- ATER 11-11-2024
- CVKD 11-07-2024
- Dividend Yield
- ATER N/A
- CVKD N/A
- EPS Growth
- ATER N/A
- CVKD N/A
- EPS
- ATER N/A
- CVKD N/A
- Revenue
- ATER $107,193,000.00
- CVKD N/A
- Revenue This Year
- ATER N/A
- CVKD N/A
- Revenue Next Year
- ATER $5.47
- CVKD N/A
- P/E Ratio
- ATER N/A
- CVKD N/A
- Revenue Growth
- ATER N/A
- CVKD N/A
- 52 Week Low
- ATER $0.23
- CVKD $5.40
- 52 Week High
- ATER $3.95
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- ATER 27.26
- CVKD 47.69
- Support Level
- ATER $2.33
- CVKD $10.65
- Resistance Level
- ATER $2.60
- CVKD $12.25
- Average True Range (ATR)
- ATER 0.16
- CVKD 1.50
- MACD
- ATER -0.03
- CVKD -0.12
- Stochastic Oscillator
- ATER 0.00
- CVKD 45.85
About ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operated brands including Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.